Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Familact 2 Plus
- Development stage
- Phase 4
- Lead developer
- Zist-Takhmir
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Familact 2 Plus is a synbiotic formulation developed by the pharmaceutical company Zist Takhmir. It is an oral capsule containing a concentrated blend of several probiotic bacterial strains combined with a prebiotic fiber, fructooligosaccharides (FOS). The probiotic component typically includes species from the *Lactobacillus*, *Bifidobacterium*, and *Streptococcus* genera, which work synergistically to restore and maintain the balance of the intestinal microbiota. The mechanism of action involves the competitive exclusion of pathogenic microorganisms, the production of antimicrobial substances such as lactic acid and bacteriocins, and the modulation of the host's mucosal immune system. It also aids in strengthening the intestinal epithelial barrier and improving digestive processes. Familact 2 Plus is primarily indicated for the management of functional gastrointestinal disorders like irritable bowel syndrome (IBS), chronic constipation, and various types of diarrhea (including antibiotic-associated and infectious diarrhea), as well as for general immune health support.
- Brand names
- Familact 2 PlusFamilact2 PlusFamilact-2 PlusFamilact
- Other names
- Familact synbiotic
Beyond the preview
Go deeper on Familact 2 Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Familact 2 Plus.